Efficacy of Pemetrexed as Second-Line Therapy in Advanced NSCLC after Either Treatment-Free Interval or Maintenance Therapy with Gemcitabine or Erlotinib in IFCT-GFPC 05-02 Phase III Study

  • Etude concernée: IFCT-0502
  • Auteurs / Authors: Bylicki O, Ferlay C, Chouaid C, Lavolé A, Barlési F, Dubos C, Westeel V, Créquit J, Corre R, Vergnenègre A, Monnet I, Le Caer H, Fournel P, Vaylet F, Falchero L, Poudenx M, Linard P, Pérol D, Zalcman G, Pérol M
  • Journal / Conference: Journal of Thoracic Oncology
  • Année / Year: 2013
  • PMID: 23591160 
  • Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/23591160